Head and Neck Oncology
Clinical research in locally advanced sinonasal carcinoma with attention to neoadjuvant treatment strategies in aggressive head and neck cancers.
- Sinonasal carcinoma
- Neoadjuvant immunotherapy
- Locally advanced disease
Work in this area centers on pembrolizumab-based approaches for tumors with high-risk local extension.
Thyroid Cancer
Research activity includes thyroid cancers, particularly high-risk thyroid carcinoma requiring preoperative treatment approaches.
- High-risk thyroid cancers
- Neoadjuvant treatment
- Immuno-oncology
The sponsor’s studies in this field focus on immune checkpoint inhibition as a therapeutic option before definitive local treatment.
Immuno-Oncology
The trial portfolio reflects interest in pembrolizumab and PD-1 blockade across rare and difficult-to-treat solid tumors.
- PD-1 inhibitor therapy
- Checkpoint inhibition
- Solid tumor immunotherapy
These studies place emphasis on immune-based cancer treatment in settings where tumor control before surgery is clinically important.
Rare Solid Tumors
Research is directed toward uncommon malignancies with limited treatment options, including rare sinonasal tumors and selected thyroid neoplasms.
- Rare malignancies
- Locally advanced tumors
- High-risk cancer subtypes
Clinical interest is concentrated in tumor types where systemic therapy may improve the management of advanced local disease.
